Rosetta Genomics Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ROSGQ research report →
About the company
Rosetta Genomics Ltd. is a global entity specializing in genomic diagnostics. The company leverages its proprietary microRNA technologies to offer a range of diagnostic assays, including RosettaGX Cancer Origin, which helps pinpoint the primary source of metastatic cancer; mi-KIDNEY, designed for classifying kidney tumors from pathological specimens; RosettaGX Reveal, used to interpret indeterminate thyroid fine-needle aspirate results; and various mi-LUNG diagnostic tests.
- CEO
- Douglas Sites
- IPO
- 2007
- Employees
- 86
- HQ
- Rehovot, IL
Price Chart
- Market Cap
- $593
- P/E
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 0.15
- Div Yield
- 0.00%
- Gross Margin
- 19.44%
- Op Margin
- -169.63%
- Net Margin
- -175.80%
- ROE
- -135.07%
- ROIC
- -189.08%
- Revenue
- $9.23M · 11.68%
- Net Income
- $-16,233,000 · 6.41%
- EPS
- $-9.31 · 32.49%
- Op Income
- $-15,664,000
- FCF YoY
- 38.45%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 5.34
- Avg Volume
- 1.82K
Get TickerSpark's AI analysis on ROSGQ
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ROSGQ coverage
Recent articles, reports, and earnings notes.
No research on ROSGQ yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ROSGQ report →Similar companies
Peers in the same neighborhood.